Recently, Sinopharm Medicinal Materials Co., Ltd. (hereinafter referred to as Medicinal Materials Co., Ltd.) and its affiliated companies have repeatedly experienced legal disputes, and there have been incidents of arrears of construction units and even rural collective enterprises. China Pharmaceutical Group Co., Ltd. (hereinafter referred to as Sinopharm Group) also often receives Complaint letter. In order to remind enterprises and institutions and the public to be vigilant and avoid damage to their interests, Sinopharm Group declares as follows:

1. from2016 year11 from January, the shareholding ratio of China Traditional Chinese Medicine Company Limited (hereinafter referred to as Sinopharm Chinese Medicine), a subsidiary of Sinopharm Group, is as follows25%. For the shares of medicinal herbs, the National Pharmaceutical Group and the National Pharmaceutical Chinese Medicine are neither controlling shareholders nor actual controllers.

2. Sinopharm Group has never authorized Medicinal Materials Co., Ltd. and its affiliated companies to carry out publicity, investment and other activities in the names of "China Pharmaceutical Group Co., Ltd.", "China Pharmaceutical Group", "Sinopharm Group", "Sinopharm Group Member Enterprises", etc., nor authorized them to use Sinopharm Group registered trademark.

The 3. has filed a lawsuit against the suspected infringement of the trademark rights and unfair competition of the Sinopharm Group. Sinopharm and Sinopharm have filed a lawsuit in accordance with the law against the fictitious shareholders' meeting, forged the resolutions of the shareholders' meeting, forged the signatures of the directors of Sinopharm and Chinese medicine, and forged and altered the articles of association. Suspected criminal acts such as forging seals on the shares of medicinal materials have been reported to the public security organs in accordance with the law.

Prior to this, Sinopharm Group and Sinopharm Chinese medicine have repeatedly issued clarification statements that have nothing to do with the behavior of medicinal materials shares and their affiliated enterprises, and hereby remind relevant subjects to strengthen prevention and beware of being deceived.

hereby declare.

2025 year2 month11